5:28 PM
 | 
Apr 17, 2013
 |  BC Extra  |  Clinical News

BioLineRx reports BL-7040 ulcerative colitis data

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from 16 evaluable patients showing that oral BL-7040 for five weeks met the primary endpoint of achieving a clinical response in a Phase IIa trial to treat moderately active...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >